E pluribus unum

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of bluebird bio, Inc. Common Stock and Sets a Lead Plaintiff Deadline of May 28, 2024

Retrieved on: 
Thursday, March 28, 2024
Sickle cell disease, AML, Telephone, Blue, District court, Patient, History, News, LLP, E pluribus unum, BLUE, FDA, Court, Bluebird bio, Food, Person

You are hereby notified that the class action lawsuit Garry Gill v. bluebird bio, Inc., et al.

Key Points: 
  • You are hereby notified that the class action lawsuit Garry Gill v. bluebird bio, Inc., et al.
  • 1:24-cv-10803) has been commenced in the United States District Court for the District of Massachusetts.
  • Following this news, Blue’s stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.
  • If you suffered a loss in BLUE common stock, you have until May 28, 2024 to request that the Court appoint you as lead plaintiff.

OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics

Retrieved on: 
Tuesday, April 2, 2024
FDA, Other Health, Practice Management, Pharmaceutical, Surgery, Managed Care, Oncology, Mental Health, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Toxicity, DPYD, Irinotecan, Clinical professor, PMID, UGT1A1, Risk, Mayo Clinic, Mental health, Wastewater treatment, Cancer, Doctor of Philosophy, MD, Medicine, E pluribus unum, Safety, Patient safety, Pain management, DPD, Colorectal cancer, Vomiting, Clinical Pharmacogenetics Implementation Consortium, Pharmaceutical industry

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.

Key Points: 
  • The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.
  • Using PGx can inform usage and dosage decisions for a wide range of chemotherapy and supportive care medications.
  • For more information about RightMed Oncology, please visit OneOmeInstitute.com/Oncology or reach out directly to discuss a PGx program for your health system.
  • OneOme aims to improve patient safety, reduce overall cost of care, and improve patients' health outcomes.

Study led by Akron Children's finds pro2cool's hypothermic therapy reduces adolescent concussion symptoms

Retrieved on: 
Tuesday, April 2, 2024
RN, Brain, Head, Medicine, Concussion, Ageing, Dayton Children's Hospital, Research, University, Doctor of Philosophy, University of Michigan, Frank R. McNinch, Adolescence, E pluribus unum, Hospital, Pain, Ice, Food, Swelling, FDA, Northeast Ohio Medical University, Parent, Neck, Sports medicine, Medical device

AKRON, Ohio, April 2, 2024 /PRNewswire/ -- Researchers at Akron Children's, Cincinnati Children's, University of Michigan and Dayton Children's Hospital, have found that hypothermic therapy reduces symptom severity after concussion.

Key Points: 
  • AKRON, Ohio, April 2, 2024 /PRNewswire/ -- Researchers at Akron Children's, Cincinnati Children's, University of Michigan and Dayton Children's Hospital, have found that hypothermic therapy reduces symptom severity after concussion.
  • After a second treatment using the pro2cool® system, SCAT5 scores were 25% lower than those receiving standard concussion care.
  • It is the first and only concussion treatment study of this population, and the largest single concussion therapy trial known to date.
  • Now, in addition to brain rest, concussion symptoms can be treated with selective hypothermic therapy.

Lowey Dannenberg, P.C. Announces an Additional Settlement for Those Who Have Transacted in Euroyen-Based Derivatives Between January 1, 2006 through June 30, 2011

Retrieved on: 
Thursday, March 21, 2024
Barclays, J. P. Morgan, Agreement, Hearing, JPMorgan Chase, E pluribus unum, HSBC (United Kingdom), HSBC Bank, HSBC, American Bankers Association, Bank, TP ICAP, Chase Bank, Singapore Exchange, UBS AG, Sumitomo Mitsui Banking Corporation, Class, Lawyer, Interbank, Citibank, National Association, Person, Citigroup, Fairness, Tokyo Financial Exchange, Negotiation, GBD, Mitsubishi Group, District court, UBS, Defendant, Vexatious litigation, Knowledge, Settlement, Resona Holdings, TP, Norinchukin Bank, Shinkin Central Bank, TFX, Prior, Government, Société Générale, Plaintiff, Notice, CME, Conspiracy theory, Chicago Mercantile Exchange, ICAP, Court

The Settlement will provide an additional $35,000,000 to pay claims from persons who transacted in Euroyen-Based Derivatives from January 1, 2006 through June 30, 2011, inclusive.

Key Points: 
  • The Settlement will provide an additional $35,000,000 to pay claims from persons who transacted in Euroyen-Based Derivatives from January 1, 2006 through June 30, 2011, inclusive.
  • Before any money is paid, the Court will hold a Fairness Hearing to decide whether to approve the Settlement.
  • Contact your brokerage firm to see if you purchased, sold, held, traded, or otherwise had any interest in Euroyen-Based Derivatives.
  • These payments will also be deducted from the Settlement Fund before any distributions are made to the Settlement Class.

Delaware Supreme Court Affirms Ruling in Favor of Texas Pacific Land Corporation on Litigation Related to Stockholders’ Agreement

Retrieved on: 
Tuesday, February 27, 2024
Oil, Gas, Energy, Commercial Building & Real Estate, Construction & Property, Utilities, Texas Pacific Land Corporation, E pluribus unum, Judgement, TPL, Delaware Court, Delaware Supreme Court, Supreme court

Texas Pacific Land Corporation (NYSE: TPL) (“TPL” or the “Company”) announced today that the Delaware Supreme Court (the “Supreme Court”) affirmed the December 1, 2023 ruling of the Delaware Court of Chancery (the “Court of Chancery”) in favor of TPL in the litigation between the Company and Horizon Kinetics LLC, Horizon Kinetics Asset Management LLC, SoftVest Advisors, LLC and SoftVest, L.P. (collectively, the “Investor Group”), in Horizon Kinetics, LLC, et al.

Key Points: 
  • Texas Pacific Land Corporation (NYSE: TPL) (“TPL” or the “Company”) announced today that the Delaware Supreme Court (the “Supreme Court”) affirmed the December 1, 2023 ruling of the Delaware Court of Chancery (the “Court of Chancery”) in favor of TPL in the litigation between the Company and Horizon Kinetics LLC, Horizon Kinetics Asset Management LLC, SoftVest Advisors, LLC and SoftVest, L.P. (collectively, the “Investor Group”), in Horizon Kinetics, LLC, et al.
  • v. Texas Pacific Land Corporation, (C.A.
  • As previously disclosed, on December 1, 2023, the Court of Chancery issued a post-trial decision ruling in favor of the Company.
  • On February 26, 2024, the Supreme Court affirmed the Court of Chancery’s post-trial decision and final judgment in favor of the Company.

Federal Judge Enters Judgment in Favor of Developer of Coachillin Business Park; Rejects Parcel Owner's Baseless Claims

Retrieved on: 
Friday, February 16, 2024
Collection, Documentation, DHS, Judgement, Deception, E pluribus unum, Developer, The Reklaws, Federal, ADV, CC, Bankruptcy

Federal Judge Enters Judgment in Favor of Developer of Coachillin Business Park; Rejects Parcel Owner's Baseless Claims

Key Points: 
  • Federal Judge Enters Judgment in Favor of Developer of Coachillin Business Park; Rejects Parcel Owner's Baseless Claims
    In a complete reversal from their initial allegations, the parcel owner agreed that the assessments, late charges, interest, and collection costs were all levied properly and consistent with the development's CC&Rs and that the assessments were all fair and reasonable.
  • In addition to the Federal court judgment, three other parcel owners entered into a settlement with the Coachillin parties.
  • Although confidential, the settlement will allow the business park to get back on its feet and move forward.
  • According to Kenneth Dickerson, managing member of the developer, "This judgment by a Federal judge is a recognition that the parcel owner's claims had zero merit.

Dallas Jury Returns $30.7 Million Verdict Against Restaurant Franchise Owner

Retrieved on: 
Wednesday, February 14, 2024
Retail, Restaurant, Bar, Legal, Professional Services, Burns, Retirement, E pluribus unum, Perales, Arby's, Sun, Burger King, LLP, Property insurance

A Dallas County jury has awarded $30.7 million in damages to a local man who claimed he had been defrauded after he did not receive a share of operating profits from the owner of roughly 150 Popeyes franchise restaurants in Texas, Oklahoma, and Florida.

Key Points: 
  • A Dallas County jury has awarded $30.7 million in damages to a local man who claimed he had been defrauded after he did not receive a share of operating profits from the owner of roughly 150 Popeyes franchise restaurants in Texas, Oklahoma, and Florida.
  • The jury initially returned a verdict of $15,618,873.47 in compensatory damages against Dallas-based Sun Holdings Inc., owner Guillermo Perales, and various subsidiaries.
  • After a bifurcated trial, the jury returned another verdict of $15,100,000.00 in punitive damages.
  • “The jury correctly concluded that Mr. Stockton had been defrauded by Mr. Perales and the other defendants.

Hilliard Shadowen LLP Files Historic Lawsuit Against NHL and CHL Alleging Exploitation of Junior Players in US & Canada

Retrieved on: 
Wednesday, February 14, 2024
NHL, Senior ice hockey, District court, E pluribus unum, National Hockey League, Ontario Hockey League, Hockey

AUSTIN, Texas, Feb. 14, 2024 /PRNewswire/ -- Hilliard Shadowen LLP, along with five other leading antitrust and labor law firms, filed a landmark antitrust case in New York federal court today, aimed at exposing what plaintiffs allege to be egregiously anticompetitive collusion that targets teenage hockey players across North America.

Key Points: 
  • The class action lawsuit challenges the alleged systematic exploitation of teens pursuing their dreams of playing in the NHL.
  • The class action lawsuit, which names as defendants the National Hockey League, the Canadian Hockey League, the Ontario Hockey League, the Western Hockey League, the Québec Maritimes Junior Hockey League, and each of those leagues' member clubs, challenges the alleged systematic exploitation of teens pursuing their dreams of playing in the NHL.
  • The case was filed by the World Association of Icehockey Players Unions North America Division, as well as two former major junior hockey players, who will seek to represent a class of similarly situated players.
  • Case Details: World Association of Icehockey Players Unions North America Division, et al.

Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline

Retrieved on: 
Wednesday, February 14, 2024
Leptin, PD, Metabolism, Toxicity, Body composition, Ciprofloxacin, Clinical Pharmacokinetics, Water, LBW, Perfusion, LBM, Canadian International Council, AUC, PLOS One, Bariatric surgery, Clopidogrel, CYP, Breast, Health, DNA-binding protein, BMC Public Health, Pharmacology, BMI, CRP, Pharmaceutical Research (journal), Organ, Draft, Guideline, Bypass surgery, WHO, Ageing, INT, Pharmacokinetics, Liver, Bioavailability, Chronic liver disease, Human, Incidence, Committee, Absorption, TBW, Cardiovascular disease, Anatomy, CYP2C19, PBPK, Cmax, Factorization of polynomials, European, Lancet, CHMP, Journal, NASH, Pharmacotherapy, Adipose tissue, Non-alcoholic fatty liver disease, Journal of Clinical Investigation, Medication package insert, Overweight, NPS MedicineWise, Permeability, Benzodiazepine, Meta-analysis, Liver disease, Half-life, Acetylcholine, Ciclosporin, AAG, Kinetics, Midazolam, Kidney, Safety, Biomarker, Clinical Pharmacology & Therapeutics, Peptide, Classification, Hypertension, Metabolic syndrome, Acute coronary syndrome, Insulin resistance, Fatty liver disease, CYP2E1, Lithium, Body mass index, Reproduction, EMA, IBW, Injection, Anker, NCA, Enzyme, Inflammation, Cancer, Weight loss, Gastrointestinal tract, Cardiac output, Public health, Adipokine, CYP2C9, E pluribus unum, Physiology, Agency, Risk, Steroid, Lymph, CYP2D6, BSA, GI, Cytokine, Systematic review, Vaccine

Reflection paper on investigations of pharmacokinetics in

Key Points: 
    • Reflection paper on investigations of pharmacokinetics in
      the obese population
      Table of contents
      1.
    • References .............................................................................................. 9

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 2/12

      1.

    • This is considered
      a shortcoming that is potentially compounded by obese patients often being poorly represented in
      clinical studies.
    • The specific aims of this reflection paper are to:
      ?

      describe how the effects of obesity can be investigated during clinical medicinal product
      development.

    • ?

      provide recommendations on when investigations of the effect of obesity on the PK of a
      medicinal product should be particularly considered.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 3/12

      ?

      discuss how to reflect PK (and/or PK/PD) findings in weight/weight-based dosing
      recommendations.

    • Absorption
      Reduced rate of absorption linked to locally reduced blood flow (8) is reported for the subcutaneous
      and transdermal routes in obese subjects.
    • Distribution
      The distribution of medicinal products is driven by body composition, regional blood flow and binding to
      tissue and plasma proteins.
    • Obese subjects have a larger absolute lean body weight (LBW) as well as fat mass.
    • The physicochemical properties of a medicinal product (lipophilicity, polarity, molecular size, and
      degree of ionization) influence its distribution in the body.
    • In BMI class III obese
      subjects, the blood flow per gram of fat is significantly lower than that observed in class I obese or
      lean subjects (4).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 4/12

      An increased amount of alpha-1-acid-glycoprotein (AAG), linked to a chronic inflammatory state, is
      reported in obese individuals.

    • Fatty infiltrations are present in the liver for 90% of obese subjects, with the extent of the infiltrations
      being proportional to the degree of obesity.
    • In some cases, in particular for CYP3A4 metabolized medicinal products,
      bodyweight normalized clearance can be lower in obese patients (23).
    • Based on presently available data, it has been suggested that uptake transporters

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 5/12

      are downregulated while efflux transporters may be upregulated (31).

    • Platelet hyper-reactivity is also observed,
      which can impair the response to anti-platelet medicinal products in obese patients (42, 43).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 6/12

      3.

      the medicinal product properties and scientific literature indicate that obesity may lead to a
      marked effect on elimination and/or distribution or on the PK/PD relationship.

    • These
      models may aid in extrapolating the known efficacy and safety in the non-obese population to the
      obese population.
    • The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients
      Before and One Year After Bariatric Surgery.
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 11/12

      41.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 12/12

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Retrieved on: 
Wednesday, February 14, 2024
Anal, International, SAN, Breast cancer, Cetuximab, SCCA, TSX, AIO, Hope, E pluribus unum, Conference, PR, Symantec Endpoint Protection, Carcinoma, Lancet, PMID, SCAC, Anal canal, Patient, Optimism, Clinical trial, Poster, Anal cancer, Pancreatic cancer, ONC, Pharmaceutical industry

SAN DIEGO and CALGARY, Alberta, Feb. 14, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA). The study was expanded based on positive data from Stage 1 of the study, presented at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) in November 2023 (link to the PR, link to the poster).

Key Points: 
  • "These exciting clinical data, which exceed the Simon two-stage success criteria, provide strong support to expand the evaluation of pelareorep in patients with advanced anal cancer.
  • "We begin the Stage 2 expansion with substantial optimism for patients and the potential of pelareorep, especially considering the initial efficacy signal observed for pelareorep-based therapy in pancreatic cancer.
  • There is currently no established standard therapy for patients with anal carcinoma who have failed first-line treatment.
  • Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.